FLT3 and B-cell chronic lymphocytic leukemia: Janssen et al. (20) developed a fully open-source drug-discovery mapping model that predicts the activity of novel kinase inhibitors in the kinome, such as the new inhibitor of FLT3. Continued progression and relapse of CLL after treatment remains problematic in patients with CLL that have been treated with new targeted agents (ibrutinib and venetoclax).